131 related articles for article (PubMed ID: 38527406)
21. Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study.
Makler A; Asghar W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982154
[TBL] [Abstract][Full Text] [Related]
22. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
Szafranska AE; Davison TS; John J; Cannon T; Sipos B; Maghnouj A; Labourier E; Hahn SA
Oncogene; 2007 Jun; 26(30):4442-52. PubMed ID: 17237814
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
[TBL] [Abstract][Full Text] [Related]
26. An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma.
Makler A; Narayanan R; Asghar W
Biosensors (Basel); 2022 Oct; 12(10):. PubMed ID: 36290970
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
Yu Q; Xu C; Yuan W; Wang C; Zhao P; Chen L; Ma J
Biomed Res Int; 2017; 2017():6495867. PubMed ID: 28466015
[No Abstract] [Full Text] [Related]
28. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
29. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
30. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
[TBL] [Abstract][Full Text] [Related]
31. miRNA-1290 Promotes Aggressiveness in Pancreatic Ductal Adenocarcinoma by Targeting IKK1.
Ta N; Huang X; Zheng K; Zhang Y; Gao Y; Deng L; Zhang B; Jiang H; Zheng J
Cell Physiol Biochem; 2018; 51(2):711-728. PubMed ID: 30463064
[TBL] [Abstract][Full Text] [Related]
32. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
33. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
[TBL] [Abstract][Full Text] [Related]
34. Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.
Wnuk J; Strzelczyk JK; Gisterek I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982210
[TBL] [Abstract][Full Text] [Related]
35. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
Xu C; Jun E; Okugawa Y; Toiyama Y; Borazanci E; Bolton J; Taketomi A; Kim SC; Shang D; Von Hoff D; Zhang G; Goel A
Gastroenterology; 2024 Jan; 166(1):178-190.e16. PubMed ID: 37839499
[TBL] [Abstract][Full Text] [Related]
36. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294.
Xu Y; Yao Y; Gao P; Cui Y
Biochem Biophys Res Commun; 2019 Jan; 509(1):138-142. PubMed ID: 30591218
[TBL] [Abstract][Full Text] [Related]
37. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
38. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
